Neumora Therapeutics (NMRA) Tax Provisions (2024 - 2026)

Neumora Therapeutics' Tax Provisions history runs 3 years deep, the most recent figure standing at $30000.0 for Q1 2026.

• In Q1 2026, Tax Provisions fell 71.43% year-over-year to $30000.0; the TTM figure through Mar 2026 stood at $5000.0 (down 98.23% YoY), while the FY2025 annual figure was $80000.0, down 55.06% from the prior year.
• Tax Provisions for Q1 2026 stood at $30000.0, up from -$50000.0 in the prior quarter.
• The five-year high for Tax Provisions was $125000.0 in Q2 2024, with the low at -$50000.0 in Q4 2025.
• The 3-year median for Tax Provisions is $41500.0 (2024), against an average of $48000.0.
• The sharpest annual moves came in 2025 and 2026: Tax Provisions sank 80.0% in 2025, then tumbled 71.43% in 2026.
• Neumora Therapeutics' Tax Provisions stood at $53000.0 in 2024, then sank by 194.34% to -$50000.0 in 2025, then jumped by 160.0% to $30000.0 in 2026.
• Business Quant data shows NMRA's Tax Provisions at $30000.0 in Q1 2026, -$50000.0 in Q4 2025, and $25000.0 in Q2 2025.